BBLG VS MOTS Stock Comparison

Performance

BBLG
10/100

BBLG returned -94.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

MOTS
10/100

MOTS returned -83.15% in the last 12 months. Based on SPY's performance of -13.96%, its performance is below average giving it a score of 10 of 100.

Technicals

BBLG
14/100

BBLG receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

MOTS
18/100

MOTS receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

Earnings

BBLG
49/100

BBLG has missed earnings 2 times in the last 20 quarters.

MOTS
74/100

MOTS has missed earnings 2 times in the last 20 quarters.

Profit

BBLG
10/100

Out of the last 20 quarters, BBLG has had 1 profitable quarters and has increased their profits year over year on 1 of them.

MOTS
10/100

Out of the last 20 quarters, MOTS has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

BBLG
46/100

BBLG has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

MOTS
46/100

MOTS has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Analyst Price Targets

BBLG

"Analyst Price Targets" not found for BBLG

MOTS
88/100

2 analysts offer 12-month price targets for MOTS. Together, they have an average target of 0, the most optimistic target put MOTS at 0 within 12-months and the most pessimistic has MOTS at 0.

All score calculations are broken down here to help you make more informed investing decisions

Bone Biologics Corp Common Stock Summary

Nasdaq / BBLG

Healthcare

Medical - Devices

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Motus GI Holdings, Inc. Common Stock Summary

Nasdaq / MOTS

Healthcare

Medical - Devices

Motus GI Holdings, Inc., a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.

Power up your portfolio